Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

IMPORTANCE: Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non–small cell lung cancer (NSCLC) are unkn...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Ferrara, Roberto, Mezquita, Laura, Texier, Matthieu, Lahmar, Jihene, Audigier-Valette, Clarisse, Tessonnier, Laurent, Mazieres, Julien, Zalcman, Gerard, Brosseau, Solenn, Le Moulec, Sylvestre, Leroy, Laura, Duchemann, Boris, Lefebvre, Corentin, Veillon, Remi, Westeel, Virginie, Koscielny, Serge, Champiat, Stephane, Ferté, Charles, Planchard, David, Remon, Jordi, Boucher, Marie-Eve, Gazzah, Anas, Adam, Julien, Bria, Emilio, Tortora, Giampaolo, Soria, Jean-Charles, Besse, Benjamin, Caramella, Caroline
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6248085/
https://ncbi.nlm.nih.gov/pubmed/30193240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.3676
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars